p3analyze:
1. I have no idea what the total amount of damage claims that the various class action attorneys have signed up, nor am I aware of how many plaintiffs may have joined the Susman Godfey "483" lawsuit. The first time that may become known is when the 60 day statutory period from the time the first law suit was filed ends on July 23 and the supervising judge has a hearing to consolidate the actions.
2. Published literature suggests that only about 1% of all successful class action lawsuits ever go to trial, with the vast majority being settled after various legal motions are decided. Settlements can be structured in a number of ways including, for example, a combination of liability insurance payments and the issuance of new shares. It would be highly unlikely that any settlement would culminate in class suitors taking control of a company.
3. I was a great believer in the science of Provenge if not in DNDN's BOD and management. I have become increasingly convinced, however, that the biggest factor in prospective Provenge efficacy is the proper sequencing of Provenge and Taxotere as Dr. Petrylak spelled out last November. Much of this relates to the important complimentary effects of long lived primed memory T cells circulating in a patient's blood and macrophages unleashed on established tumors by the action of Taxotere, as Petrylak pointed out and as work of Ulrich von Andrian of Harvard that was unrelated to Provenge predicts. Since DNDN has all that PA2024 in storage and the FDA is allowing them to ship clinical trial Provenge while they work out production problems, a compassionate use, open label trial using Petrylak's suggested protocol could be a good way to rehabilitate DNDN's science as well as its reputation in the oncology clinical investigator community without burning too much cash. JMHO.
